Top Markets
#1 DogBull DogBull +73.55%
#2 Siren Siren +31.86%
#3 OriginTrail OriginTrail +16.42%
#4 Verus Coin Verus Coin +9.51%
#5 MarsCoin MarsCoin +7.48%
#6 COTI COTI +6.57%
#7 Tutorial Tutorial +6.56%
#8 Falcon Finance Falcon Finance +6.28%
#9 PulseChain PulseChain +6.04%
#10 HOME HOME +5.95%
Coin of the day
DogBull DogBull
Settings
Language
ENGLISH
Currency
USD
Theme
AlzeCure Pharma AB AlzeCure Pharma AB

AlzeCure Pharma AB

ALZCUR
Rank in Stocks #22112
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops... AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer’s disease, sleep disorders, depression, traumatic brain injuries, and Parkinson’s disease, which is in phase I clinical trial; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer’s disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain indications; and ACD137, negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications. The company was founded in 2012 and is based in Huddinge, Sweden.
Share Price
$0.71707249
Last synced: 2026-08-21
Market Cap
$94.14M
Change (1 day)
-3.31%
Change (1 year)
76.82%
Country
SE
Trade AlzeCure Pharma AB (ALZCUR)

Category

Healthcare
Revenue for AlzeCure Pharma AB (ALZCUR)
Revenue in Aug 2026 TTM: 0
According to AlzeCure Pharma AB latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for AlzeCure Pharma AB from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH